NO20064059L - Albumin fusjonsproteiner - Google Patents

Albumin fusjonsproteiner

Info

Publication number
NO20064059L
NO20064059L NO20064059A NO20064059A NO20064059L NO 20064059 L NO20064059 L NO 20064059L NO 20064059 A NO20064059 A NO 20064059A NO 20064059 A NO20064059 A NO 20064059A NO 20064059 L NO20064059 L NO 20064059L
Authority
NO
Norway
Prior art keywords
vectors
albumin infusion
proteins
fusion proteins
infusion proteins
Prior art date
Application number
NO20064059A
Other languages
English (en)
Inventor
Craig A Rosen
William A Haseltine
Paul A Moore
Jason B Bock
Adam Bell
Yanggu Shi
David Lafleur
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of NO20064059L publication Critical patent/NO20064059L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)

Abstract

Foreliggende oppfinnelse omfatter albuminfusjonsproteiner. Nukleinsyremolekyler som koder for albuminfusjonsproteinene ifølge oppfinnelsen omfattes også av oppfinnelsen, og likeså vektorer som inneholder disse nukleinsyrene, vertsceller som er transformert med disse nukleinsyrevektorene og fremgangsmåter for fremstilling av albuminfusjonsproteinene ifølge oppfinnelsen og anvendelse av disse nukleinsyrene, vektorene og/eller vertscellene. I tillegg omfatter foreliggende oppfinnelse farmasøytiske preparater som omfatter albuminfusjonsproteiner og fremgangsmåter for behandling, forebyggelse eller lindring av sykdommer, forstyrrelser eller tilstander ved anvendelse av albuminfusjonsproteiner ifølge oppfinnelsen
NO20064059A 2004-02-09 2006-09-08 Albumin fusjonsproteiner NO20064059L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54227404P 2004-02-09 2004-02-09
US54990104P 2004-03-05 2004-03-05
US55690604P 2004-03-29 2004-03-29
US63660304P 2004-12-17 2004-12-17
PCT/US2005/004041 WO2005077042A2 (en) 2004-02-09 2005-02-09 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
NO20064059L true NO20064059L (no) 2006-11-02

Family

ID=34865403

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064059A NO20064059L (no) 2004-02-09 2006-09-08 Albumin fusjonsproteiner

Country Status (20)

Country Link
US (3) US7569384B2 (no)
EP (1) EP1729795B1 (no)
JP (2) JP5010923B2 (no)
KR (1) KR101184391B1 (no)
CN (1) CN102816241B (no)
AU (2) AU2005211725B2 (no)
BR (1) BRPI0507026A (no)
CA (1) CA2554089C (no)
CY (1) CY1117401T1 (no)
DK (1) DK1729795T3 (no)
ES (1) ES2567634T3 (no)
HU (1) HUE027902T2 (no)
IL (1) IL176894A (no)
MA (1) MA28565B1 (no)
MX (1) MXPA06009072A (no)
NO (1) NO20064059L (no)
NZ (1) NZ548612A (no)
PL (1) PL1729795T3 (no)
SI (1) SI1729795T1 (no)
WO (1) WO2005077042A2 (no)

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1631496B1 (en) * 2003-04-28 2014-02-26 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
KR20070084069A (ko) 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
MX2008001865A (es) * 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
EP1929073A4 (en) * 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
ES2586236T3 (es) * 2005-11-04 2016-10-13 Glaxosmithkline Llc Procedimientos para administrar agentes hipoglucémicos
US20080280328A1 (en) * 2005-11-18 2008-11-13 Novozymes A/S Glucoamylase Variants
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007249668B2 (en) 2006-04-11 2011-04-07 Novartis Ag HCV/HIV inhibitors and their uses
US7966746B2 (en) * 2006-04-24 2011-06-28 Medical Instill Technologies, LLC Needle penetrable and laser resealable lyophilization method
US8334365B2 (en) 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
TWI430806B (zh) * 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
JP2010503396A (ja) * 2006-09-14 2010-02-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
WO2008052043A2 (en) * 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
AU2008211227B2 (en) 2007-01-30 2014-04-17 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
RU2361607C2 (ru) * 2007-06-09 2009-07-20 Государственное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию Российской Федерации" Способ локальной иммунотерапии гнойно-воспалительных заболеваний мягких тканей челюстно-лицевой области
WO2009012502A1 (en) * 2007-07-19 2009-01-22 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Self- anchoring mems intrafascicular neural electrode
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
WO2009030373A1 (en) * 2007-09-05 2009-03-12 Sanofi-Aventis Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
WO2009116557A1 (ja) * 2008-03-21 2009-09-24 富士フイルム株式会社 薬剤含有組成物
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
US20110300127A1 (en) * 2008-05-27 2011-12-08 Fujifilm Corporation Drug-containing composition
US8748377B2 (en) 2008-12-10 2014-06-10 Glaxosmithkline Llc Pharmaceutical compositions
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
CN102405236A (zh) 2009-02-19 2012-04-04 葛兰素集团有限公司 改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
CN102458442B (zh) * 2009-04-08 2016-06-29 加利福尼亚大学董事会 具有受控血清药代动力学的人蛋白支架
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
KR101286721B1 (ko) * 2009-06-05 2013-07-16 한국과학기술연구원 폴리-시스테인 펩티드 융합 재조합 알부민 및 이의 제조방법
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP2453920A2 (en) 2009-07-16 2012-05-23 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
BR112012001977A2 (pt) 2009-07-29 2017-01-31 Glaxo Group Ltd domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar.
AU2010290131C1 (en) * 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
BR112012010114A2 (pt) 2009-10-27 2017-08-08 Glaxo Group Ltd domínio variável único de imunoglobulina, ligante multiespecífico, antagonista, uso do antagonista, método para tratamento e/ou profilaxia de uma condição inflamatória em um paciente, ácido nucleico, vetor, e, célula hospedeira.
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
US20120308517A1 (en) 2010-02-09 2012-12-06 Digna Biotech, S.L. Compositions for the treatment of infectious and tumoural diseases
KR20130010461A (ko) 2010-02-18 2013-01-28 브리스톨-마이어스 스큅 컴퍼니 Ｉｌ―２３에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EA022983B1 (ru) 2010-04-13 2016-04-29 Бристол-Майерс Сквибб Компани Белки на основе структурного домена фибронектина, связывающие pcsk9
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
BR112012029611A2 (pt) * 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
ES2573108T3 (es) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
WO2012013597A1 (de) * 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
EA201390532A1 (ru) 2010-10-08 2013-09-30 Новартис Аг Композиции сульфамидых ингибиторов ns3, содержащие витамин е
JP2014504587A (ja) 2010-12-22 2014-02-24 ブリストル−マイヤーズ スクイブ カンパニー Ｉｌ−２３に結合するフィブロネクチンをベースとするスカフォールドドメインタンパク質
JP6062375B2 (ja) 2011-01-06 2017-01-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド
US20140080153A1 (en) * 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
RU2650784C2 (ru) 2011-05-05 2018-04-17 Альбумедикс А/С Варианты альбумина
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP2773659A2 (en) 2011-10-31 2014-09-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CN117462693A (zh) 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
WO2013138338A2 (en) 2012-03-12 2013-09-19 Massachusetts Institute Of Technology Methods for treating tissue damage associated with ischemia with apoliporotein d
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013135896A1 (en) 2012-03-16 2013-09-19 Novozymes Biopharma Dk A/S Albumin variants
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
CN104768571B (zh) 2012-07-13 2018-11-09 酵活有限公司 多价异多聚体支架设计和构建体
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
TWI633117B (zh) 2012-09-13 2018-08-21 必治妥美雅史谷比公司 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
EP2951206A2 (en) 2013-02-01 2015-12-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014138371A1 (en) 2013-03-06 2014-09-12 Glaxosmithkline Llc Host cells and methods of use
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en) * 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
EA037554B1 (ru) 2013-03-15 2021-04-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Анти-lag-3 связывающие белки
RU2646098C2 (ru) 2013-04-30 2018-03-01 Интас Фармасьютикалс Лтд Новый способ клонирования, экспрессии и очистки для получения ранибизумаба
ES2739280T3 (es) 2013-07-04 2020-01-30 Glykos Finland Oy Células fúngicas filamentosas deficientes en O-manosiltransferasa y métodos de uso de las mismas
EP3035950A4 (en) * 2013-08-14 2017-05-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
CN105377882B (zh) * 2014-03-06 2020-05-05 葛兰素史密斯克莱有限责任公司 宿主细胞和使用方法
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
SG11201700446XA (en) 2014-07-21 2017-02-27 Glykos Finland Oy Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
JP6800141B2 (ja) 2014-08-12 2020-12-16 マサチューセッツ インスティテュート オブ テクノロジー Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
ES2981335T3 (es) 2014-11-25 2024-10-08 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
MX385081B (es) 2014-11-25 2025-03-14 Bristol Myers Squibb Co Métodos y composiciones para radioetiquetado con 18f de productos biológicos.
EP3234116B1 (en) 2014-12-19 2021-09-08 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
US10407490B2 (en) 2015-04-24 2019-09-10 VIIV Healthcare UK (No.5) Limited Polypeptides targeting HIV fusion
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
KR20250073532A (ko) 2015-09-02 2025-05-27 이뮤텝 에스.에이.에스. 항-lag-3 항체
SI3348635T1 (sl) * 2015-09-08 2021-08-31 Jcr Pharmaceuticals Co., Ltd. Novi mutant humanega serumskega albumina
SG11201802180TA (en) * 2015-09-18 2018-04-27 Univ Miyazaki Long-acting adrenomedullin derivative
ES2809125T3 (es) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Moléculas de armazón a base de fibronectina de unión a glipicano-3
CN110317264B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
CN108697768B (zh) 2015-12-23 2022-07-22 约翰霍普金斯大学 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
EP3431508A4 (en) * 2016-03-14 2019-08-14 JCR Pharmaceuticals Co., Ltd. SERUM ALBUMIN-20-K-GROWTH HORMONE FUSION PROTEIN
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
CN110090295B (zh) * 2018-01-29 2022-12-23 武汉康理通科技有限公司 Ephrin-B1在制备治疗炎症性肠病的药物中的用途
WO2019152827A1 (en) * 2018-02-02 2019-08-08 AskGene Pharma, Inc. Novel antibody-drug conjugates (adc), methods of making, and methods of use thereof
BR112020016454A8 (pt) 2018-02-12 2022-08-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Tratamento utilizando rna que codifica citocina
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
EP3806889A4 (en) 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
MX2021000801A (es) 2018-07-24 2021-04-12 BioNTech SE Agonistas de il2.
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
US20220098252A1 (en) 2019-01-25 2022-03-31 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
US20220125836A1 (en) 2019-02-08 2022-04-28 Biontech Cell & Gene Therapies Gmbh Treatment involving car-engineered t cells and cytokines
EP3941935A1 (en) 2019-03-18 2022-01-26 Biontech Cell & Gene Therapies Gmbh Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
WO2020200481A1 (en) 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Treatment involving interleukin-2 (il2) and interferon (ifn)
WO2020214690A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
TW202115105A (zh) 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
RU2714392C1 (ru) * 2019-07-09 2020-02-14 Екатерина Олеговна Кудасова Способ модификации поверхности метилметакрилата стоматологического протеза низкотемпературной газоразрядной плазмой кислорода низкого давления за счет изменения контактного угла смачивания по воде и свободной поверхностной энергии
KR20220044534A (ko) 2019-08-13 2022-04-08 엘피스 바이오파마슈티컬즈 조작된 인터류킨-2 수용체 베타 효능제
WO2021058091A1 (en) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Treatment involving therapeutic antibody and interleukin-2 (il2)
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
WO2021129927A1 (en) 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
WO2021129945A1 (en) 2019-12-27 2021-07-01 Biontech Cell & Gene Therapies Gmbh In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)
JP2023515633A (ja) 2020-02-28 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用
CA3171370A1 (en) 2020-03-16 2021-09-23 Ugur Sahin Antigen-specific t cell receptors and t cell epitopes
WO2021197589A1 (en) 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1
JPWO2022030580A1 (no) * 2020-08-06 2022-02-10
KR102467827B1 (ko) * 2020-08-31 2022-11-16 연세대학교 산학협력단 미생물 에어로졸화 과정 중 발생하는 손상 방지 방법
CN112724259B (zh) * 2020-11-16 2022-12-20 天津林达生物科技有限公司 人血清白蛋白与白介素2的融合蛋白及其用途
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
CN112753846B (zh) * 2021-01-27 2023-08-29 吉林农业大学 一种超持水大豆分离蛋白凝胶及其制备方法
AU2022256732A1 (en) 2021-04-12 2023-10-19 Biontech Delivery Technologies Gmbh Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
AU2022260466A1 (en) 2021-04-20 2023-11-02 BioNTech SE Virus vaccine
WO2022241310A1 (en) * 2021-05-14 2022-11-17 Antlia Bioscience, Inc. Modified b-type natriuretic peptide
BR112023025194A2 (pt) 2021-06-04 2024-02-27 Boehringer Ingelheim Int Anticorpos anti-sirp-alfa
CN113391067B (zh) * 2021-06-16 2023-07-25 军事科学院军事医学研究院军事兽医研究所 抗尼帕病毒g蛋白抗体的间接elisa检测方法
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
CN118302189A (zh) 2021-10-21 2024-07-05 生物技术欧洲股份公司 冠状病毒疫苗
JP2024540948A (ja) 2021-10-22 2024-11-06 ビオンテック・ソシエタス・エウロパエア 異なる投与のｒｎａを投与するための組成物
WO2023083434A1 (en) 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
WO2023126053A1 (en) 2021-12-28 2023-07-06 BioNTech SE Lipid-based formulations for administration of rna
WO2023141638A1 (en) * 2022-01-21 2023-07-27 The Methodist Hospital System Methods for vascular regeneration and wound treatment
WO2023165681A1 (en) 2022-03-01 2023-09-07 BioNTech SE Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer
WO2023193892A1 (en) 2022-04-05 2023-10-12 BioNTech SE Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
CA3251835A1 (en) 2022-05-10 2023-11-16 Elpis Biopharmaceuticals MODIFIED INTERLEUKIN-2 BETA RECEPTOR REDUCED LINK AGONIST
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
AU2023317702A1 (en) 2022-08-01 2025-01-09 BioNTech SE Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
WO2024027910A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
CA3263686A1 (en) 2022-08-03 2024-02-08 BioNTech SE RNA FOR THE PREVENTION OR TREATMENT OF TUBERCULOSIS
CN115960175A (zh) * 2022-08-08 2023-04-14 江南大学 一种强化乳铁蛋白表达的毕赤酵母及其构建方法与应用
JP2024056667A (ja) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 血清アルブミンと生理活性を有する蛋白質との融合蛋白質
JP2024056665A (ja) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 血清アルブミンと生理活性を有する蛋白質との融合蛋白質
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
WO2024153324A1 (en) 2023-01-18 2024-07-25 BioNTech SE Rna formulations for pharmaceutical use
WO2024213776A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
WO2024216212A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
WO2024216214A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
AU2024308069A1 (en) 2023-06-27 2026-02-05 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
WO2025021277A1 (en) 2023-07-21 2025-01-30 BioNTech SE Agents and methods for targeted delivery of cytokines to immune cells
WO2025026866A1 (en) 2023-07-28 2025-02-06 BioNTech SE Rna therapeutics with reduced toxicity
TW202535461A (zh) 2023-10-06 2025-09-16 德商百靈佳殷格翰國際股份有限公司 使用抗ｓｉｒｐａ抗體治療肝臟疾病或病症
TW202535460A (zh) 2023-10-06 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗ＳＩＲＰ－α抗體用於治療癌症之用途
CN117511986B (zh) * 2023-10-17 2026-04-10 广州立白企业集团有限公司 一种构建多基因改造酵母菌的方法及其应用
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
TW202602919A (zh) 2024-03-01 2026-01-16 德商百靈佳殷格翰國際股份有限公司 結締組織生長因子(ctgf)之抗體及其用途
WO2026042013A1 (en) 2024-08-19 2026-02-26 Institute Of Molecular And Clinical Ophthalmology Basel (Iob) Mitochondrial therapy
CN120591344B (zh) * 2025-06-13 2026-04-03 广州景旸生物科技有限公司 Col3a1蛋白的制备方法及其应用

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988008027A1 (en) * 1987-04-09 1988-10-20 Delta Biotechnology Limited Yeast vector
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
ZA894792B (en) 1988-06-24 1991-04-24 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
WO1989012631A1 (en) 1988-06-24 1989-12-28 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
CA1320162C (en) 1988-08-11 1993-07-13 California Biotechnology Inc. Method for stabilizing heterologous protein expression and vectors for use therein
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
US5667986A (en) * 1989-10-18 1997-09-16 Delta Biotechnology Limited Yeast promoter for expressing heterologous polypeptides
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9013017D0 (en) * 1990-06-11 1990-08-01 Mars Uk Ltd Compounds
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5225341A (en) 1990-07-19 1993-07-06 The Regents Of The University Of California Biologically safe plant transformation system using a ds transposon
US5202239A (en) * 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
JPH07108232B2 (ja) 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
US5646012A (en) * 1991-04-30 1997-07-08 Rhone-Poulenc Rorer S.A. Yeast promoter and use thereof
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
FR2686620B1 (fr) * 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa Serum-albumine humaine, preparation et utilisation.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
ES2153385T5 (es) 1992-07-31 2008-09-01 Genentech, Inc. Composicion acuosa a base de hormona del crecimiento humana.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
US5512459A (en) 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK144093D0 (no) * 1993-12-23 1993-12-23 Novo Nordisk As
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US5623054A (en) 1994-06-23 1997-04-22 The General Hospital Corporation Crucifer AFT proteins and uses thereof
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP0910578A2 (en) 1996-01-19 1999-04-28 The Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DE69717092T2 (de) 1996-03-01 2003-07-24 Novo Nordisk A/S, Bagsvaerd Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997034911A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6110703A (en) * 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
AU3972797A (en) * 1996-08-02 1998-02-25 Zymogenetics Inc. Testis-specific insulin homolog polypeptides
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
WO1998011136A1 (en) 1996-09-09 1998-03-19 Novo Nordisk A/S A cDNA AND PEPTIDE WITH RELATION TO CANCER AND WEIGHT LOSS
WO1998012344A1 (en) 1996-09-18 1998-03-26 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP1306092A3 (en) 1996-11-05 2003-05-07 Eli Lilly & Company Use of GLP-1 and analogs administered peripherally, in regulation of obesity
JP2001504105A (ja) 1996-11-12 2001-03-27 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１ペプチドの利用
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
JP2001527387A (ja) * 1997-01-24 2001-12-25 ノボ ノルディスク アクティーゼルスカブ 合成リーダーペプチド配列
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
US20030175858A1 (en) * 1997-03-07 2003-09-18 Ruben Steven M. 186 human secreted proteins
US6420526B1 (en) * 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
US20030065139A1 (en) * 1998-03-19 2003-04-03 Craig A. Rosen Secreted protein hmmbd35
US20030049618A1 (en) * 1997-03-07 2003-03-13 Ruben Steven M. 186 human secreted proteins
US20060084082A1 (en) * 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9713412D0 (en) 1997-06-26 1997-08-27 Delta Biotechnology Ltd Improved protein expression strains
NZ503343A (en) 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
AU753157B2 (en) 1997-11-03 2002-10-10 Georgetown University Medical Center VEGI, an inhibitor of angiogenesis and tumor growth
JP2002512175A (ja) 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
US7205280B2 (en) * 1998-03-11 2007-04-17 Cognosci, Inc. Methods of suppressing microglial activation
ATE339507T1 (de) * 1998-06-15 2006-10-15 Gtc Biotherapeutics Inc Erythropoietin-analog-menschliches serum-albumin fusionsprotein
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
CA2363712C (en) 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20020048571A1 (en) 1999-07-19 2002-04-25 Jeno Gyuris Chimeric polypeptides of serum albumin and uses related thereto
IL147714A0 (en) 1999-07-19 2002-08-14 Gpc Biotech Inc Chimeric polypeptides of serum albumin and uses related thereto
EP2206720A1 (en) * 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
ATE397938T1 (de) 2000-05-19 2008-07-15 Amylin Pharmaceuticals Inc Behandlung des akuten koronaren syndroms mit glp- 1
WO2002034285A2 (en) 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
BR0116024A (pt) * 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
WO2002097038A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
WO2003042354A2 (en) * 2001-09-04 2003-05-22 Aventis Pharmaceuticals Inc. Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
AU2002332041A1 (en) * 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1458860A2 (en) 2001-12-21 2004-09-22 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2003084563A1 (en) 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
US20070270339A1 (en) * 2004-04-23 2007-11-22 Serono, Inc. Use of GPCR54 Ligands for the Treatment of Infertility
WO2006073890A2 (en) 2004-12-24 2006-07-13 Amylin Pharmaceuticals, Inc. Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
WO2006110887A2 (en) 2005-04-11 2006-10-19 Amylin Pharmaceuticals, Inc Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
MX2008001865A (es) 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
AU2007267833B2 (en) 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
US8334365B2 (en) 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
EP2068910A2 (en) 2006-08-04 2009-06-17 Amylin Pharmaceuticals, Inc. Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
JP5005450B2 (ja) * 2007-07-13 2012-08-22 本田技研工業株式会社 燃料給油管の口元内部構造

Also Published As

Publication number Publication date
EP1729795A4 (en) 2008-05-21
US7569384B2 (en) 2009-08-04
KR20070016119A (ko) 2007-02-07
JP2007522806A (ja) 2007-08-16
US20070027306A1 (en) 2007-02-01
AU2005211725B2 (en) 2010-07-15
KR101184391B1 (ko) 2013-03-14
MA28565B1 (fr) 2007-05-02
EP1729795B1 (en) 2016-02-03
EP1729795A2 (en) 2006-12-13
WO2005077042A2 (en) 2005-08-25
WO2005077042A3 (en) 2006-11-30
IL176894A (en) 2012-08-30
SI1729795T1 (sl) 2016-04-29
ES2567634T3 (es) 2016-04-25
AU2010227035A1 (en) 2010-11-04
BRPI0507026A (pt) 2007-04-17
CN102816241A (zh) 2012-12-12
US8143026B2 (en) 2012-03-27
NZ548612A (en) 2009-11-27
AU2005211725A1 (en) 2005-08-25
JP5568582B2 (ja) 2014-08-06
JP2012140448A (ja) 2012-07-26
IL176894A0 (en) 2006-12-10
MXPA06009072A (es) 2007-03-29
US20100093627A1 (en) 2010-04-15
DK1729795T3 (en) 2016-04-11
JP5010923B2 (ja) 2012-08-29
US20070048282A1 (en) 2007-03-01
HK1095087A1 (zh) 2007-04-27
CA2554089C (en) 2013-10-22
CY1117401T1 (el) 2017-04-26
CN102816241B (zh) 2015-07-22
PL1729795T3 (pl) 2016-08-31
CA2554089A1 (en) 2005-08-25
HUE027902T2 (en) 2016-11-28

Similar Documents

Publication Publication Date Title
NO20064059L (no) Albumin fusjonsproteiner
NO20081233L (no) Albumin fusjonsproteiner
MX2009002816A (es) Proteinas de fusion de albumina.
WO2007146038A3 (en) Albumin fusion proteins
WO2005003296A3 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
WO2001079444A3 (en) Albumin fusion proteins
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
BR112014007469A2 (pt) arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas
WO2003030821A3 (en) Albumin fusion proteins
WO2007092772A8 (en) Protein formulations
JOP20190083A1 (ar) بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2277888A3 (en) Fusion proteins of albumin and erythropoietin
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
NO20054769L (no) Substituerte fenylalkansyrer
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
DK1888641T3 (da) Serumalbuminbindende proteiner
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
WO2007123765A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
NO20052276L (no) Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapi
ATE520708T1 (de) Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: HUMAN GENOME SCIENCES INC., US

FC2A Withdrawal, rejection or dismissal of laid open patent application